The effects of anti-TNF-α treatment with adalimumab on growth in children with Crohn's disease (CD)

Journal of Crohn's and Colitis

Volumn 6, Issue 3, 2012, Pages 337-344

  Malik, S ^a   Ahmed, S F ^a   Wilson, M L ^b   Shah, N ^c   Loganathan, S ^d   Naik, S ^e   Bourke, B ^f   Thomas, A ^g   Akobeng, A K ^g   Fagbemi, A ^g   Wilson, D C ^b   Russell, R K ^a  

^a ROYAL HOSPITAL FOR SICK CHILDREN   (United Kingdom)

^b UNIVERSITY OF EDINBURGH   (United Kingdom)

^c GREAT ORMOND STREET HOSPITAL   (United Kingdom)

^d ROYAL ABERDEEN CHILDREN S HOSPITAL   (United Kingdom)

^e Barts and the London Children's Hospital   (United Kingdom)

^f OUR LADY S CHILDREN S HOSPITAL   (Ireland)

^g ROYAL MANCHESTER CHILDREN S HOSPITAL   (United Kingdom)

Author keywords

Adalimumab; Crohn's disease; Growth; Inflammatory bowel disease

Indexed keywords

ADALIMUMAB; INFLIXIMAB; PREDNISOLONE;

ADOLESCENT; ARTICLE; BODY HEIGHT; CHILD; CHILD GROWTH; CLINICAL ARTICLE; CROHN DISEASE; DISEASE ACTIVITY; DRUG HYPERSENSITIVITY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MALE; PRIORITY JOURNAL; REMISSION; SCHOOL CHILD; TREATMENT INDICATION;

ADOLESCENT; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL, HUMANIZED; BODY HEIGHT; CHILD; CROHN DISEASE; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; METHOTREXATE; PREDNISOLONE; PUBERTY; REMISSION INDUCTION; STATISTICS, NONPARAMETRIC; TIME FACTORS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84858078186     PISSN: 18739946     EISSN: 18764479     Source Type: Journal    
DOI: 10.1016/j.crohns.2011.09.004     Document Type: Article

References (50)

1. Savage M.O., Beattie R.M., Camacho-Hubner C., Walker-Smith J.A., Sanderson I.R. Growth in Crohn's disease. Acta Paediatr Suppl 1999, 88(428):89-92.
2. Wong S.C., MacRae V.E., McGrogan P., Ahmed S.F. The role of pro-inflammatory cytokines in inflammatory bowel disease growth retardation. J Pediatr Gastroenterol Nutr 2006, 43(2):144-155.
3. Vermeire S., Van A.G., Rutgeerts P. Review article: altering the natural history of Crohn's disease - evidence for and against current therapies. Aliment Pharmacol Ther 2007, 25(1):3-12. 1.
4. Newby E.A., Sawczenko A., Thomas A.G., Wilson D. Interventions for growth failure in childhood Crohn's disease. Cochrane Database Syst Rev 2005, CD003873.
5. Hyams J., Crandall W., Kugathasan S., Griffiths A., Olson A., Johanns J., et al. Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn's disease in children. Gastroenterology 2007, 132(3):863-873.
6. Colombel J.F., Sandborn W.J., Rutgeerts P., Enns R., Hanauer S.B., Panaccione R., et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology 2007, 132(1):52-65.
7. Sandborn W.J., Rutgeerts P., Enns R., Hanauer S.B., Colombel J.F., Panaccione R., et al. Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial. Ann Intern Med 2007, 146(12):829-838. 19.
8. Peyrin-Biroulet L., Laclotte C., Bigard M.A. Adalimumab maintenance therapy for Crohn's disease with intolerance or lost response to infliximab: an open-label study. Aliment Pharmacol Ther 2007, 25(6):675-680. 15.
9. Ho G.T., Smith L., Aitken S., Lee H.M., Ting T., Fennell J., et al. The use of adalimumab in the management of refractory Crohn's disease. Aliment Pharmacol Ther 2008, 27(4):308-315. 15.
10. Hinojosa J., Gomollon F., Garcia S., Bastida G., Cabriada J.L., Saro C., et al. Efficacy and safety of short-term adalimumab treatment in patients with active Crohn's disease who lost response or showed intolerance to infliximab: a prospective, open-label, multicentre trial. Aliment Pharmacol Ther 2007, 25(4):409-418. 15.
11. Borrelli O., Bascietto C., Viola F., Bueno dM, Barbato M., Mancini V., et al. Infliximab heals intestinal inflammatory lesions and restores growth in children with Crohn's disease. Dig Liver Dis 2004, 36(5):342-347.
12. Cezard J.P., Nouaili N., Talbotec C., Hugot J.P., Gobert J.G., Schmitz J., et al. A prospective study of the efficacy and tolerance of a chimeric antibody to tumor necrosis factors (remicade) in severe pediatric crohn disease. J Pediatr Gastroenterol Nutr 2003, 36(5):632-636.
13. Pfefferkorn M., Burke G., Griffiths A., Markowitz J., Rosh J., Mack D., et al. Growth abnormalities persist in newly diagnosed children with crohn disease despite current treatment paradigms. J Pediatr Gastroenterol Nutr 2009, 48(2):168-174.
14. Thayu M., Leonard M.B., Hyams J.S., Crandall W.V., Kugathasan S., Otley A.R., et al. Improvement in biomarkers of bone formation during infliximab therapy in pediatric Crohn's disease: results of the REACH study. Clin Gastroenterol Hepatol 2008, 6(12):1378-1384.
15. Walters T.D., Gilman A.R., Griffiths A.M. Linear growth improves during infliximab therapy in children with chronically active severe Crohn's disease. Inflamm Bowel Dis 2007, 13(4):424-430.
16. Malik S., Wong S.C., Bishop J., Hassan K., McGrogan P., Ahmed S.F., et al. Improvement in growth of children with Crohn disease following anti-TNF-alpha therapy can be independent of pubertal progress and glucocorticoid reduction. J Pediatr Gastroenterol Nutr 2011, 52(1):31-37.
17. Sinitsky D.M., Lemberg D.A., Leach S.T., Bohane T.D., Jackson R., Day A.S. Infliximab improves inflammation and anthropometric measures in pediatric Crohn's disease. J Gastroenterol Hepatol 2010, 25(4):810-816.
18. Diamanti A., Basso M.S., Gambarara M., Papadatou B., Bracci F., Noto C., et al. Positive impact of blocking tumor necrosis factor alpha on the nutritional status in pediatric Crohn's disease patients. Int J Colorectal Dis 2009, 24(1):19-25.
19. Wewer V., Riis L., Vind I., Husby S., Munkholm P., Paerregaard A. Infliximab dependency in a national cohort of children with Crohn's disease. J Pediatr Gastroenterol Nutr 2006, 42(1):40-45.
20. Mian S., Baron H. Adalimumab, a novel anti-tumor necrosis factor-alpha antibody in a child with refractory Crohn's disease. J Pediatr Gastroenterol Nutr 2005, 41(3):357-359.
21. Nguyen K.D., Alexis R., Schwarz S.M. Oropharyngeal and proximal esophageal involvement during adalimumab treatment of Crohn disease. J Pediatr Gastroenterol Nutr 2010, 50(2):225-226.
22. Noe J.D., Pfefferkorn M. Short-term response to adalimumab in childhood inflammatory bowel disease. Inflamm Bowel Dis 2008, 14(12):1683-1687.
23. Rosenbach Y., Hartman C., Shapiro R., Hirsch A., Avitzur Y., Shamir R. Adalimumab treatment in children with refractory Crohn's disease. Dig Dis Sci 2010, 55(3):747-753.
24. Rosh J.R., Lerer T., Markowitz J., Goli S.R., Mamula P., Noe J.D., et al. Retrospective Evaluation of the Safety and Effect of Adalimumab Therapy (RESEAT) in pediatric Crohn's disease. Am J Gastroenterol 2009, 104(12):3042-3049.
25. Veres G., Putz R., Szabo D., Molnar K., Bodanszky H., Dezsofi A., et al. [Adalimumab treatment in infliximab-resistant pediatric patient with Crohn's disease]. Orv Hetil 2009 4, 150(40):1858-1860.
26. Wyneski M.J., Green A., Kay M., Wyllie R., Mahajan L. Safety and efficacy of adalimumab in pediatric patients with Crohn disease. J Pediatr Gastroenterol Nutr 2008, 47(1):19-25.
27. Viola F., Civitelli F., Di N.G., Barbato M.B., Borrelli O., Oliva S., et al. Efficacy of adalimumab in moderate-to-severe pediatric Crohn's disease. Am J Gastroenterol 2009, 104(10):2566-2571.
28. Russell R.K., Wilson M.L., Loganathan S., Bourke B., Kiparissi F., Mahdi G., et al. A British Society of Paediatric Gastroenterology, Hepatology and Nutrition survey of the effectiveness and safety of adalimumab in children with inflammatory bowel disease. Aliment Pharmacol Ther 2011, 33(8):946-953.
29. Inflammatory bowel disease in children and adolescents: recommendations for diagnosis-the Porto criteria 69. J Pediatr Gastroenterol Nutr 2005, 41(1):1-7. IBD Working Group of the European Society for Paediatric Gastroenterology HaNE.
30. Silverberg M.S., Satsangi J., Ahmad T., Arnott I.D., Bernstein C.N., Brant S.R., et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: Report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol 2005, 19:5-36. Suppl A.
31. Morris N.M., Udry J.R. Validation of a self-administered instrument to assess stage of adolescent development. J Youth Adolesc 1980, 9(3):271-280. 1.
32. Petersen A.C., Crockett L., Richards M., Boxer A. A self-report measure of pubertal status: reliability, validity, and initial norms. J Youth Adolesc 1988, 17(2):117-133. 1.
33. Cole T.J., Freeman J.V., Preece M.A. Body mass index reference curves for the UK, 1990. Arch Dis Child 1995, 73(1):25-29.
34. Freeman J.V., Cole T.J., Chinn S., Jones P.R., White E.M., Preece M.A. Cross sectional stature and weight reference curves for the UK, 1990. Arch Dis Child 1995, 73(1):17-24.
35. Satsangi J., Silverberg M.S., Vermeire S., Colombel J.F. The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications. Gut 2006, 55(6):749-753.
36. Hyams J.S., Ferry G.D., Mandel F.S., Gryboski J.D., Kibort P.M., Kirschner B.S., et al. Development and validation of a pediatric Crohn's disease activity index. J Pediatr Gastroenterol Nutr 1991, 12(4):439-447.
37. Turner D., Griffiths A.M., Walters T.D., Seah T., Markowitz J., Pfefferkorn M., et al. Appraisal of the pediatric Crohn's disease activity index on four prospectively collected datasets: recommended cutoff values and clinimetric properties. Am J Gastroenterol 2010, 105(9):2085-2092.
38. Van A.G. Immunogenicity of anti-TNF antibodies. Has the veil been lifted?. Gut 2011, 60(3):285-286.
39. Giannini E.H., Ilowite N.T., Lovell D.J., Wallace C.A., Rabinovich C.E., Reiff A., et al. Effects of long-term etanercept treatment on growth in children with selected categories of juvenile idiopathic arthritis. Arthritis Rheum 2010, 62(11):3259-3264.
40. Billiau A.D., Loop M., Le P.Q., Berthet F., Philippet P., Kasran A., et al. Etanercept improves linear growth and bone mass acquisition in MTX-resistant polyarticular-course juvenile idiopathic arthritis. Rheumatology (Oxford) 2010, 49(8):1550-1558.
41. Ballinger A.B., Savage M.O., Sanderson I.R. Delayed puberty associated with inflammatory bowel disease. Pediatr Res 2003, 53(2):205-210.
42. Dziechciarz P., Horvath A., Shamir R., Szajewska H. Meta-analysis: enteral nutrition in active Crohn's disease in children. Aliment Pharmacol Ther 2007, 26(6):795-806. 15.
43. Beattie R.M., Camacho-Hubner C., Wacharasindhu S., Cotterill A.M., Walker-Smith J.A., Savage M.O. Responsiveness of IGF-I and IGFBP-3 to therapeutic intervention in children and adolescents with Crohn's disease. Clin Endocrinol (Oxf) 1998, 49(4):483-489.
44. Thomas A.G., Holly J.M., Taylor F., Miller V. Insulin like growth factor-I, insulin like growth factor binding protein-1, and insulin in childhood Crohn's disease. Gut 1993, 34(7):944-947.
45. Belli D.C., Seidman E., Bouthillier L., Weber A.M., Roy C.C., Pletincx M., et al. Chronic intermittent elemental diet improves growth failure in children with Crohn's disease. Gastroenterology 1988, 94(3):603-610.
46. Aiges H., Markowitz J., Rosa J., Daum F. Home nocturnal supplemental nasogastric feedings in growth-retarded adolescents with Crohn's disease. Gastroenterology 1989, 97(4):905-910.
47. Wong S.C., Hassan K., McGrogan P., Weaver L.T., Ahmed S.F. The effects of recombinant human growth hormone on linear growth in children with Crohn's disease and short stature. J Pediatr Endocrinol Metab 2007, 20(12):1315-1324.
48. Wong S.C., Smyth A., McNeill E., Galloway P.J., Hassan K., McGrogan P., et al. The growth hormone insulin-like growth factor 1 axis in children and adolescents with inflammatory bowel disease and growth retardation. Clin Endocrinol (Oxf) 2010, 73(2):220-228.
49. Vasseur F., Gower-Rousseau C., Vernier-Massouille G., Dupas J.L., Merle V., Merlin B., et al. Nutritional status and growth in pediatric Crohn's disease: a population-based study. Am J Gastroenterol 2010, 105(8):1893-1900.
50. Hyams J., Griffiths A.M., Markowitz J., Baldassano R., Faubion W., Colletti R., et al. Induction and maintenance adalimumab therapy for the treatment of moderate to severe Crohn's disease in children. 6th Congress of the European Crohn's and Colitis Organisation 2011.